Browse > Article
http://dx.doi.org/10.4069/kjwhn.2021.01.19

What influences aromatase inhibitor continuation intention among breast cancer survivors?  

Seo, Young Kyung (College of Nursing, Yonsei University)
Park, Jeongok (College of Nursing, Mo-Im Kim Nursing Research Institute, Yonsei University)
Park, Jin-Hee (College of Nursing, Research Institute of Nursing Science, Ajou University)
Kim, Sue (College of Nursing, Mo-Im Kim Nursing Research Institute, Yonsei University)
Publication Information
Women's Health Nursing / v.27, no.1, 2021 , pp. 49-57 More about this Journal
Abstract
Purpose: Aromatase inhibitors (AIs) are widely prescribed for postmenopausal women with breast cancer and are known to cause musculoskeletal pain. This study aimed to identify factors associated with AI continuation intention among breast cancer survivors (BCS). Methods: A cross-sectional survey was conducted on 123 BCS (stages I-III), who had been taking AIs for at least 6 weeks. Participants were recruited from a cancer center in Goyang, Korea, from September to November 2019. Descriptive statistics, Welch analysis of variance, Pearson correlation coefficients, and simple linear regression were used for the analysis. Results: Beliefs about endocrine therapy was a significant predictor of AI continuation intention (β=.66, p<.001). The majority of participants (87.0%) reported experiencing musculoskeletal pain since taking AIs and the score for the worst pain severity within 24 hours was 5.08±2.80 out of 10. Musculoskeletal pain, however, was not associated with AI continuation intention. Fear of cancer recurrence (FCR) was clinically significant (≥13) for 74.0% of the respondents (mean, 17.62±7.14). Musculoskeletal pain severity and pain interference were significantly associated with FCR (r=.21, p<.05; r=.35, p<.01, respectively). Pain interference was significantly associated with beliefs about endocrine therapy (r=-.18, p<.05). Conclusion: AI continuation intention can be modified by reinforcing patients' beliefs about endocrine therapy. Musculoskeletal pain may have a negative effect on beliefs about endocrine therapy and increase FCR among BCS. Thus, awareness of musculoskeletal pain during AI therapy should be raised and further research is required to develop multidisciplinary pain management strategies and clinical guidelines to reinforce beliefs about endocrine therapy.
Keywords
Aromatase inhibitor; Breast cancer; Medication adherence; Musculoskeletal pain;
Citations & Related Records
연도 인용수 순위
  • Reference
1 de Mendoza AH, Cabling M, Dilawari A, Turner JW, Fernandez N, Henderson A, et al. Providers' perspectives on adherence to hormonal therapy in breast cancer survivors. is there a role for the Digital Health Feedback System? Health Technol (Berl). 2019;9(2):175-184. https://doi.org/10.1007/s12553-018-0267-x   DOI
2 Emanuel G, Henson KE, Broggio J, Charman J, Horgan K, Dodwell D, et al. Endocrine therapy in the years following a diagnosis of breast cancer: a proof of concept study using the primary care prescription database linked to cancer registration data. Cancer Epidemiol. 2019;61:185-189. https://doi.org/10.1016/j.canep.2019.04.012   DOI
3 Xing P, Dong H, Liu Q, Yao F, Xu Y, Chen B, et al. Impact of persistence on survival of patients with breast cancer treated with endocrine therapy in Northeast China: a prospective study. Oncotarget. 2017;8(60):102499-102510. https://doi.org/10.18632/oncotarget.18454   DOI
4 Beryl LL, Rendle KA, Halley MC, Gillespie KA, May SG, Glover J, et al. Mapping the decision-making process for adjuvant endocrine therapy for breast cancer: the role of decisional resolve. Med Decis Making. 2017;37(1):79-90. https://doi.org/10.1177/0272989X16640488   DOI
5 Lambert LK, Balneaves LG, Howard AF, Chia SK, Gotay CC. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors. BMC Cancer. 2018;18(1):732. https://doi.org/10.1186/s12885-018-4644-7   DOI
6 Corter AL, Broom R, Porter D, Harvey V, Findlay M. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer. Psychooncology. 2018; 27(9):2096-2103. https://doi.org/10.1002/pon.4771   DOI
7 Park JY, Lee SK, Bae SY, Kim J, Kim MK, Kil WH, et al. Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors. J Korean Surg Soc. 2013;85(5): 205-211. https://doi.org/10.4174/jkss.2013.85.5.205   DOI
8 Pakpour AH, Gellert P, Asefzadeh S, Updegraff JA, Molloy GJ, Sniehotta FF. Intention and planning predicting medication adherence following coronary artery bypass graft surgery. J Psychosom Res. 2014;77(4):287-295. https://doi.org/10.1016/j.jpsychores.2014.07.001   DOI
9 Chim K, Xie SX, Stricker CT, Li QS, Gross R, Farrar JT, et al. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors. BMC Cancer. 2013;13:401. https://doi.org/10.1186/1471-2407-13-401   DOI
10 Lombard JM, Zdenkowski N, Wells K, Beckmore C, Reaby L, Forbes JF, et al. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options. Support Care Cancer. 2016;24(5):2139-2146. https://doi.org/10.1007/s00520-015-3001-5   DOI
11 Kim TH, Kang JW, Lee TH. Therapeutic options for aromatase inhibitor-associated arthralgia in breast cancer survivors: A systematic review of systematic reviews, evidence mapping, and network meta-analysis. Maturitas. 2018;118:29-37. https://doi.org/10.1016/j.maturitas.2018.09.005   DOI
12 Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, et al. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer. 2013;119(13):2375-2382. https://doi.org/10.1002/cncr.28016   DOI
13 Cahir C, Dombrowski SU, Kelly CM, Kennedy MJ, Bennett K, Sharp L. Women's experiences of hormonal therapy for breast cancer: exploring influences on medication-taking behaviour. Support Care Cancer. 2015;23(11):3115-3130. https://doi.org/10.1007/s00520-015-2685-x   DOI
14 Lee JY, Min YH. Relationships between determinants of adjuvant endocrine therapy adherence in breast cancer. BMC Womens Health. 2018;18(1):48. https://doi.org/10.1186/s12905-018-0522-3   DOI
15 Hall DL, Lennes IT, Pirl WF, Friedman ER, Park ER. Fear of recurrence or progression as a link between somatic symptoms and perceived stress among cancer survivors. Support Care Cancer. 2017;25(5):1401-1407. https://doi.org/10.1007/s00520-016-3533-3   DOI
16 Lopez C, Charles C, Rouby P, Boinon D, Laurent S, Rey A, et al. Relations between arthralgia and fear of recurrence: results of a cross-sectional study of breast cancer patients treated with adjuvant aromatase inhibitors therapy. Support Care Cancer. 2015;23(12):3581-3588. https://doi.org/10.1007/s00520-015-2722-9   DOI
17 Salgado TM, Davis EJ, Farris KB, Fawaz S, Batra P, Henry NL. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer. Breast Cancer Res Treat. 2017;163(2):311-319. https://doi.org/10.1007/s10549-017-4177-9   DOI
18 Lee YH, Jeong IS. Factors influencing medication adherence to oral anticancer drugs. Asian Oncol Nurs. 2013;13(4):201-209. https://doi.org/10.5388/aon.213.13.4.201   DOI
19 Yun YH, Mendoza TR, Heo DS, Yoo T, Heo BY, Park HA, et al. Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology. 2004;66(6):439-444. https://doi.org/10.1159/000079497   DOI
20 Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, et al. Patient-reported outcomes and early discontinuation in aromatase inhibitor-treated postmenopausal women with early stage breast cancer. Oncologist. 2016;21(5):539-546. https://doi.org/10.1634/theoncologist.2015-0349   DOI
21 Simard S, Savard J. Fear of Cancer Recurrence Inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer. 2009;17(3):241-251. https://doi.org/10.1007/s00520-008-0444-y   DOI
22 Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. 1994;23(2):129-138.
23 Simard S, Savard J. Screening and comorbidity of clinical levels of fear of cancer recurrence. J Cancer Surviv. 2015;9(3):481-491. https://doi.org/10.1007/s11764-015-0424-4   DOI
24 Shin J, Goo A, Ko H, Kim JH, Lim SU, Lee HK, Simard S, et al. Validation study for the korean version of Fear of Cancer Recurrence Inventory. J Korean Med Sci. 2017;32(11):1792-1799. https://doi.org/10.3346/jkms.2017.32.11.1792   DOI
25 Kim SH. Development of an adjuvant endocrine therapy beliefs scale for breast cancer survivors [dissertation]. Seoul: Yonsei University; 2019 . 215p.
26 Boonstra A, van Zadelhoff J, Timmer-Bonte A, Ottevanger PB, Beurskens CH, van Laarhoven HW. Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers. Cancer Nurs. 2013;36(1):52-59. https://doi.org/10.1097/NCC.0b013e31824a7e18   DOI
27 Shim HY, Park M, Kim HJ, Kyung HS, Shin JY. Physical activity status by pain severity in patients with knee osteoarthritis: a nationwide study in Korea. BMC Musculoskelet Disord. 2018;19(1):380. https://doi.org/10.1186/s12891-018-2301-6   DOI
28 Cleeland CS. The brief pain inventory user guide. Houston (TX): MD Anderson Cancer Center; 2009.
29 Heisig SR, Shedden-Mora MC, von Blanckenburg P, Rief W, Witzel I, Albert US, et al. What do women with breast cancer expect from their treatment? Correlates of negative treatment expectations about endocrine therapy. Psychooncology. 2016;25(12):1485-1492. https://doi.org/10.1002/pon.4089   DOI